Literature DB >> 21481791

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Olga A Guryanova1, Qiulian Wu, Lin Cheng, Justin D Lathia, Zhi Huang, Jinbo Yang, Jennifer MacSwords, Christine E Eyler, Roger E McLendon, John M Heddleston, Weinian Shou, Dolores Hambardzumyan, Jeongwu Lee, Anita B Hjelmeland, Andrew E Sloan, Markus Bredel, George R Stark, Jeremy N Rich, Shideng Bao.   

Abstract

Glioblastomas display cellular hierarchies containing tumor-propagating glioblastoma stem cells (GSCs). STAT3 is a critical signaling node in GSC maintenance but molecular mechanisms underlying STAT3 activation in GSCs are poorly defined. Here we demonstrate that the bone marrow X-linked (BMX) nonreceptor tyrosine kinase activates STAT3 signaling to maintain self-renewal and tumorigenic potential of GSCs. BMX is differentially expressed in GSCs relative to nonstem cancer cells and neural progenitors. BMX knockdown potently inhibited STAT3 activation, expression of GSC transcription factors, and growth of GSC-derived intracranial tumors. Constitutively active STAT3 rescued the effects of BMX downregulation, supporting that BMX signals through STAT3 in GSCs. These data demonstrate that BMX represents a GSC therapeutic target and reinforces the importance of STAT3 signaling in stem-like cancer phenotypes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481791      PMCID: PMC3076106          DOI: 10.1016/j.ccr.2011.03.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  54 in total

1.  Integrin alpha 6 regulates glioblastoma stem cells.

Authors:  Justin D Lathia; Joseph Gallagher; John M Heddleston; Jialiang Wang; Christine E Eyler; Jennifer Macswords; Qiulian Wu; Amit Vasanji; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

2.  Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis.

Authors:  Shi Pan; Ping An; Rong Zhang; Xiangrong He; Guoyong Yin; Wang Min
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

3.  Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain.

Authors:  R Chen; O Kim; M Li; X Xiong; J L Guan; H J Kung; H Chen; Y Shimizu; Y Qiu
Journal:  Nat Cell Biol       Date:  2001-05       Impact factor: 28.824

4.  Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.

Authors:  Linlang Guo; Yuanyuan Zhou; Yanqin Sun; Fan Zhang
Journal:  Eur J Cancer       Date:  2009-12-11       Impact factor: 9.162

5.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

6.  Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  Stat3 activation is required for the growth of U87 cell-derived tumours in mice.

Authors:  Atreyi Dasgupta; Baisakhi Raychaudhuri; Talat Haqqi; Richard Prayson; Erwin G Van Meir; Michael Vogelbaum; Saikh Jaharul Haque
Journal:  Eur J Cancer       Date:  2008-12-31       Impact factor: 9.162

Review 9.  Antiangiogenic therapy in malignant glioma: promise and challenge.

Authors:  Sith Sathornsumetee; Jeremy N Rich
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

View more
  141 in total

1.  FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Authors:  Ai-Hua Gong; Ping Wei; Sicong Zhang; Jun Yao; Ying Yuan; Ai-Dong Zhou; Frederick F Lang; Amy B Heimberger; Ganesh Rao; Suyun Huang
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

2.  Genomics informs glioblastoma biology.

Authors:  David L Schonberg; Shideng Bao; Jeremy N Rich
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

Review 3.  Brain Tumor Stem Cells Remain in Play.

Authors:  Luis F Parada; Peter B Dirks; Robert J Wechsler-Reya
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

4.  Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.

Authors:  Yu Shi; Olga A Guryanova; Wenchao Zhou; Chong Liu; Zhi Huang; Xiaoguang Fang; Xiuxing Wang; Cong Chen; Qiulian Wu; Zhicheng He; Wei Wang; Wei Zhang; Tao Jiang; Qing Liu; Yaping Chen; Wenying Wang; Jingjing Wu; Leo Kim; Ryan C Gimple; Hua Feng; Hsiang-Fu Kung; Jennifer S Yu; Jeremy N Rich; Yi-Fang Ping; Xiu-Wu Bian; Shideng Bao
Journal:  Sci Transl Med       Date:  2018-05-30       Impact factor: 17.956

Review 5.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

6.  Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Authors:  Jun Fu; Dimpy Koul; Jun Yao; Shuzhen Wang; Ying Yuan; Howard Colman; Erik P Sulman; Frederick F Lang; W K Alfred Yung
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

7.  mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells.

Authors:  Daming Zhang; Guang Yang; Xin Chen; Chunmei Li; Lu Wang; Yaohua Liu; Dayong Han; Huailei Liu; Xu Hou; Weiguang Zhang; Chenguang Li; Zhanqiang Han; Xin Gao; Shiguang Zhao
Journal:  J Mol Neurosci       Date:  2014-01-28       Impact factor: 3.444

8.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

9.  Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.

Authors:  Sen Chen; Xinnong Jiang; Christina A Gewinner; John M Asara; Nicholas I Simon; Changmeng Cai; Lewis C Cantley; Steven P Balk
Journal:  Sci Signal       Date:  2013-05-28       Impact factor: 8.192

Review 10.  The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment.

Authors:  Elizabeth A Stoll; Philip J Horner; Robert C Rostomily
Journal:  Aging Cell       Date:  2013-06-28       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.